Pancreatic Cancer

Clinical Trials

Mayo Clinic physicians recently completed a clinical trial comparing the standard Whipple operation with extended lymphadenectomy.

Below is a list of Pancreatic Cancer clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

MC0542 - Phase II Study of 17-N-Allylamino-17- Demethoxygeldanamycin (17-AAG) (Tanespimycin) In Combination With Gemcitabine (Gemzar) In Patients With Metastatic Pancreatic Cancer
Patients are being asked to take part in this research study to find out the effects (good and bad) of the combination of gemcitabine and 17AAG has on a patient and their metastatic pancreatic cancer. Gemcitabine is a chemotherapy drug approved by the U.S. Food and Drug Administration (FDA) for use in metastatic pancreatic cancer. 17AAG is an investigational or experimental anti-cancer agent that has not yet been approved by the FDA for use in metastatic pancreatic cancer.
Read more

A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with Gemcitabine (Gemzar) in Patients with Advanced Pancreatic Cancer
Patients are being asked to take part in this research study because they have advanced pancreatic cancer and are a candidate for chemotherapy with a drug called gemcitabine, which is currently a standard treatment for pancreatic cancer.

This study is being done to find out what dose of a new drug, named AEG35156, given in combination with the standard chemotherapy drug, gemcitabine, will work the best and without causing unacceptable side effects.

The study drug AEG35156 is not approved by the U.S. Food and Drug Administration (FDA) for use outside of this clinical study. Gemcitabine is a chemotherapy drug which has been approved by FDA for the treatment of advance pancreatic cancer.

The primary purpose of this study is to:
- Find out how much of the study drug (AEG35156), when taken with standard doses of gemcitabine, can be given without causing bad side effects
- See if the study drug can improve the effectiveness of the gemcitabine
Read more

Biospecimen Resource for Familial Pancreas Research, a Data and Tissue Registry (also known as a bio-repository, bio-bank, data and tissue database, data and tissue bank, etc.) to Help Advance Research in Familial Pancreas Disease.
The research staff is collecting clinical and family histories, blood and/or tissue samples from family members of patients diagnosed with pancreatic diseases, including pancreatic cancer and melanoma. This will help the researchers to learn whether inherited factors increase the risk of pancreatic diseases, pancreatic cancer, or other cancers. These future studies could involve searching for changes in the genetic material (DNA) taken from blood and/or tissue. The information and samples will be used in future research studies.

Some of the future research studies could involve genetic testing. Because the genetic tests are not used for regular medical care, the patient will not be told the results of the test(s). The test results will not be put in the patient's medical record either.

Read more

Biospecimen Resource for Pancreas Research, a Data & Tissue Bank (also known as a bio-repository, bio-bank, data & tissue database, data & tissue registry, etc.) to Help Advance Research in Pancreas Disease.
This study is being done to develop better ways to screen people at risk for pancreatic conditions, including pancreatic cancer. It is being done to try to find new genes or substances that may make some people more likely to develop pancreatic conditions, and to find agents that may help to prevent, treat, or cure them.

The research staff is collecting clinical and family histories, blood and/or tissue samples from patients diagnosed with pancreatic diseases, including pancreatic cancer. This will help the researchers to learn whether inherited factors increase the risk of pancreatic diseases, pancreatic cancer, or other cancers. These studies will involve searching for changes in the genetic material (DNA) taken from blood and/or tissue. The information and samples will be used in current and future research studies.

Some of the future research studies could involve genetic testing. Because the genetic tests are not used for regular medical care, patients will not be told the results of the test(s). The test results will not be put in the patient's medical record either.
Read more

Supplemental Method of Controlling Pain in Pancreatic Cancer Patients
The purpose of this trial is to determine the effectiveness of celiac plexus neurolysis as an adjunct to standard medical therapy for pain control in patients with unresectable pancreatic cancer and moderate to severe pain.
Read more